|
|
OX47, CD147, pg 42kD, expression increases on activation, Clone: OX-47, Mab anti-Rat, flow
|
OX47, CD147, pg 42kD, expression increases on activation, Clone: OX-47, Mab anti-Rat, flow
|
|
|
1,3,2-Oxazaborolidine, 3,4-dimethyl-2,5-diphenyl- |
1,3,2-Oxazaborolidine, 3,4-dimethyl-2,5-diphenyl- |
|
|
Oxayohimban-16-carboxylic acid, 16,17-didehydro-19-methyl-, (19-alpha, 20-alpha)-, compd. with 1H-imidazole (1:1) |
Oxayohimban-16-carboxylic acid, 16,17-didehydro-19-methyl-, (19-alpha, 20-alpha)-, compd. with 1H-imidazole (1:1) |
|
|
Oxayohimban-16-carboxylic acid, 16,17-didehydro-19-methyl-, (19-alpha, 20-alpha)-, compd. with 2-aminoethanol (1:1) |
Oxayohimban-16-carboxylic acid, 16,17-didehydro-19-methyl-, (19-alpha, 20-alpha)-, compd. with 2-aminoethanol (1:1) |
|
|
[1,3]Oxazepino[3,2-a]benzimidazole,2,3,4,5-tetrahydro-(9CI) |
[1,3]Oxazepino[3,2-a]benzimidazole,2,3,4,5-tetrahydro-(9CI) |
|
|
1,4-Oxazepine,2,3,4,7-tetrahydro-4,6-dimethyl-(9CI) |
1,4-Oxazepine,2,3,4,7-tetrahydro-4,6-dimethyl-(9CI) |
|
|
1,4-Oxazepino[6,7-c][1,8]naphthyridin-6(2H)-one,3,7-dihydro-(9CI) |
1,4-Oxazepino[6,7-c][1,8]naphthyridin-6(2H)-one,3,7-dihydro-(9CI) |
|
|
[1,4]Oxazino[3,4-a]isoquinoline,1,3,4,6,7,11b-hexahydro-3,3-dimethyl-(8CI) |
[1,4]Oxazino[3,4-a]isoquinoline,1,3,4,6,7,11b-hexahydro-3,3-dimethyl-(8CI) |
|
|
[1,4]Oxazino[4,3-a]quinoxaline,1,2,4,4a,5,6-hexahydro-(9CI) |
[1,4]Oxazino[4,3-a]quinoxaline,1,2,4,4a,5,6-hexahydro-(9CI) |
|
|
[1,4]Oxazino[3,4-a]isoquinoline,1,3,4,6,7,11b-hexahydro-3-methyl-(8CI) |
[1,4]Oxazino[3,4-a]isoquinoline,1,3,4,6,7,11b-hexahydro-3-methyl-(8CI) |
|
|
|